Literature DB >> 10952570

Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis.

G P Morlock1, J T Crawford, W R Butler, S E Brim, D Sikes, G H Mazurek, C L Woodley, R C Cooksey.   

Abstract

We examined the correlation of mutations in the pyrazinamidase (PZase) gene (pncA) with the pyrazinamide (PZA) resistance phenotype with 60 Mycobacterium tuberculosis isolates. PZase activity was determined by the method of Wayne (L. G. Wayne, Am. Rev. Respir. Dis. 109:147-151, 1974), and the entire pncA nucleotide sequence, including the 74 bp upstream of the start codon, was determined. PZA susceptibility testing was performed by the method of proportions on modified Middlebrook and Cohn 7H10 medium. The PZA MICs were > or =100 microg/ml for 37 isolates, 34 of which had alterations in the pncA gene. These mutations included missense substitutions for 24 isolates, nonsense substitutions for 3 isolates, frameshifts by deletion for 4 isolates, a three-codon insertion for 1 isolate, and putative regulatory mutations for 2 isolates. Among 21 isolates for which PZA MICs were <100 microg/ml, 3 had the same mutation (Thr47-->Ala) and 18 had the wild-type sequence. For the three Thr47-->Ala mutants PZA MICs were 12.5 microg/ml by the method of proportions on 7H10 agar; two of these were resistant to 100 microg of PZA per ml and the third was resistant to 800 microg of PZA per ml by the BACTEC method. In all, 30 different pncA mutations were found among the 37 pncA mutants. No PZase activity was detected in 35 of 37 strains that were resistant to > or =100 microg of PZA per ml or in 34 of 37 pncA mutants. Reduced PZase activity was found in the three mutants with the Thr47-->Ala mutation. This study demonstrates that mutations in the pncA gene may serve as a reliable indicator of resistance to > or =100 microg of PZA per ml.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952570      PMCID: PMC90060          DOI: 10.1128/AAC.44.9.2291-2295.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  M Mestdagh; P A Fonteyne; L Realini; R Rossau; G Jannes; W Mijs; K A De Smet; F Portaels; E Van den Eeckhout
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system--New York, 1991.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1992-07-17       Impact factor: 17.586

3.  Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations.

Authors:  L Heifets; P Lindholm-Levy
Journal:  Am Rev Respir Dis       Date:  1992-05

4.  Quality control of individual components used in Middlebrook 7H10 medium for mycobacterial susceptibility testing.

Authors:  L S Guthertz; M E Griffith; E G Ford; J M Janda; T F Midura
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

5.  The action of antituberculosis drugs in short-course chemotherapy.

Authors:  D A Mitchison
Journal:  Tubercle       Date:  1985-09

6.  Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity.

Authors:  W R Butler; J O Kilburn
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

7.  Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months.

Authors: 
Journal:  Tubercle       Date:  1981-06

8.  Rapid radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  M Salfinger; L B Reller; B Demchuk; Z T Johnson
Journal:  Res Microbiol       Date:  1989 May-Jun       Impact factor: 3.992

9.  Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis.

Authors:  V G Coronado; C M Beck-Sague; M D Hutton; B J Davis; P Nicholas; C Villareal; C L Woodley; J O Kilburn; J T Crawford; T R Frieden
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

10.  Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility.

Authors:  J K McClatchy; A Y Tsang; M S Cernich
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

View more
  47 in total

1.  Temperature-mediated heteroduplex analysis performed by using denaturing high-performance liquid chromatography to identify sequence polymorphisms in Mycobacterium tuberculosis complex organisms.

Authors:  Robert C Cooksey; Glenn P Morlock; Brian P Holloway; Josef Limor; Michael Hepburn
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

2.  Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan.

Authors:  Tsi-Shu Huang; Susan Shin-Jung Lee; Hui-Zin Tu; Wen-Kuei Huang; Yao-Shen Chen; Chung-Kai Huang; Shue-Ren Wann; Hsi-Hsun Lin; Yung-Ching Liu
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal.

Authors:  Isabel Portugal; Luís Barreiro; José Moniz-Pereira; Laura Brum
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

4.  Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia.

Authors:  Tatjana Tracevska; Inta Jansone; Viesturs Baumanis; Anda Nodieva; Olgerts Marga; Girts Skenders
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

5.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil.

Authors:  Vívian de F Sumnienski Rodrigues; Maria Alice Telles; Marta Osório Ribeiro; Patrícia Izquierdo Cafrune; Maria Lucia Rosa Rossetti; Arnaldo Zaha
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Pamela Chedore; Lina Bertucci; Joyce Wolfe; Meenu Sharma; Frances Jamieson
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

7.  Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States.

Authors:  M M Hannan; E P Desmond; G P Morlock; G H Mazurek; J T Crawford
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

8.  Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.

Authors:  Vanessa Mathys; René Wintjens; Philippe Lefevre; Julie Bertout; Amit Singhal; Mehdi Kiass; Natalia Kurepina; Xiao-Ming Wang; Barun Mathema; Alain Baulard; Barry N Kreiswirth; Pablo Bifani
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

9.  Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.

Authors:  Jirarut Jonmalung; Therdsak Prammananan; Manoon Leechawengwongs; Angkana Chaiprasert
Journal:  BMC Microbiol       Date:  2010-08-20       Impact factor: 3.605

10.  Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.

Authors:  Muthuraj Muthaiah; Sridharan Jagadeesan; Nisha Ayalusamy; Manupriya Sreenivasan; Sambamurthy Sangamesvara Prabhu; Usharani Muthuraj; Kamatchiyammal Senthilkumar; Saroja Veerappan
Journal:  Int J Mol Sci       Date:  2010-07-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.